 New York, New York--Newsfile Corp. - June 17, 2021 - PCG Digital -- Lexaria Bioscience Corp. NASDAQ: LEXX hit a major milestone this week with their patented DehydraTECHTM technology. An IC50 in vitro study was completed with COVID-19 SARS-CoV-2 antivirals Remdesivir and Ebastine and concluded that their formulation and processing methodology did not negate the known efficacy of those compounds. This test is conducted as a passfail, said Chris Bunka, CEO of Lexaria Bioscience... 